Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience.

Adult Aged Antimetabolites, Antineoplastic / administration & dosage Breast Neoplasms / drug therapy Capecitabine / administration & dosage Drug Administration Schedule Female Humans Kaplan-Meier Estimate Middle Aged Retrospective Studies Treatment Failure
Capecitabine Dosing schedules Metastatic breast cancer Survival analysis

Journal

Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330

Informations de publication

Date de publication:
10 2020
Historique:
received: 07 11 2019
accepted: 02 01 2020
pubmed: 16 1 2020
medline: 3 9 2021
entrez: 16 1 2020
Statut: ppublish

Résumé

Purpose Capecitabine is widely used as a single agent on a 21-day cycle in the management of metastatic breast cancer (MBC). Our primary objective was to compare the standard dosing of capecitabine (Arm A: days 1-14 on 21-day cycle) to biweekly dosing (Arm B: days 1-7 and 15-21 on 28-day cycle) using retrospective data analysis. Methods 166 patients with MBC treated with single agent capecitabine at The Ohio State University from 2002 to 2014 were considered eligible. Median time to treatment failure (TTF) and overall survival (OS) were estimated using Kaplan-Meier (KM) methods. KM curves were compared using log-rank tests with Holm's correction for multiplicity. Results Patients were grouped by dose schedule into one of three arms: Arm A (21-day cycle; capecitabine given at 1000 mg/m

Identifiants

DOI: 10.1007/s10637-020-00891-9 PMID: 31938949
pubmed: 31938949
doi: 10.1007/s10637-020-00891-9
pii: 10.1007/s10637-020-00891-9
doi:

Substances chimiques

Antimetabolites, Antineoplastic 0
Capecitabine 6804DJ8Z9U

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1605-1611

Subventions

Organisme : NCATS NIH HHS
ID : UL1TR002733
Pays : United States
Organisme : Cancer Clinical Investigator Team Leadership Award
ID : P30CA016058-42S2
Pays : International

Références

Noone AM, Howlader N, Krapcho M et al (2018) SEER Cancer statistics review, 1975–2015. National Cancer Institute, Bethesda
Mayer EL, Burstein HJ (2007) Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 21:257–272. https://doi.org/10.1016/j.hoc.2007.03.001
doi: 10.1016/j.hoc.2007.03.001 pubmed: 17512448
Genetech USA Inc (2016) Xeloda [package insert]
Schellens JHM (2007) Capecitabine. Oncologist 12:152–155. https://doi.org/10.1634/theoncologist.12-2-152
doi: 10.1634/theoncologist.12-2-152 pubmed: 17296810
Fumoleau P, Largillier R, Clippe C et al (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536–542. https://doi.org/10.1016/j.ejca.2003.11.007
doi: 10.1016/j.ejca.2003.11.007 pubmed: 14962720
Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al (2003) Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227–1233. https://doi.org/10.1093/annonc/mdg346
Oshaughnessy JA, Blum J, Moiseyenko V et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247–1254
doi: 10.1023/A:1012281104865
Bajetta E, Procopio G, Celio L et al (2005) Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23:2155–2161. https://doi.org/10.1200/JCO.2005.02.167
doi: 10.1200/JCO.2005.02.167 pubmed: 15710946
Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217. https://doi.org/10.1200/JCO.2007.12.6557
doi: 10.1200/JCO.2007.12.6557 pubmed: 17968020
Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743. https://doi.org/10.1056/NEJMoa064320
doi: 10.1056/NEJMoa064320 pubmed: 17192538
Bartsch R, Wenzel C, Altorjai G et al (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25:3853–3858. https://doi.org/10.1200/JCO.2007.11.9776
doi: 10.1200/JCO.2007.11.9776 pubmed: 17679724
Scheithauer W, Kornek GV, Raderer M et al (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21:1307–1312. https://doi.org/10.1200/JCO.2003.09.016
doi: 10.1200/JCO.2003.09.016 pubmed: 12663719
Traina TA, Theodoulou M, Feigin K et al (2008) Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 26:1797–1802. https://doi.org/10.1200/JCO.2007.13.8388
doi: 10.1200/JCO.2007.13.8388 pubmed: 18398145
Gajria D, Feigin K, Tan LK et al (2011) Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer 117:4125–4131. https://doi.org/10.1002/cncr.25992
doi: 10.1002/cncr.25992 pubmed: 21387266
Hennessy BT, Gauthier AM, Michaud LB et al (2005) Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer center and a review of capecitabine toxicity in the literature. Ann Oncol 16:1289–1296. https://doi.org/10.1093/annonc/mdi253
doi: 10.1093/annonc/mdi253 pubmed: 15890665
Zielinski C, Gralow J, Martin M (2010) Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 21:2145–2152. https://doi.org/10.1093/annonc/mdq069
doi: 10.1093/annonc/mdq069 pubmed: 20332132
Nishijima TF, Suzuki M, Muss HB (2016) A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 156:227–236. https://doi.org/10.1007/s10549-016-3756-5
doi: 10.1007/s10549-016-3756-5 pubmed: 26988358 pmcid: 4988831
Traina TA, Dugan U, Higgins B et al (2010) Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. Breast Dis 31:7–18. https://doi.org/10.3233/BD-2009-0290
doi: 10.3233/BD-2009-0290 pubmed: 20519801 pmcid: 3228251
Cadoo KA, Gajria D, Suh E et al (2016) Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review. NPJ Breast Cancer 2:16006. https://doi.org/10.1038/npjbcancer.2016.6
doi: 10.1038/npjbcancer.2016.6 pubmed: 28721374 pmcid: 5515341

Auteurs

Anupama Suresh (A)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Akannsha Ganju (A)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Evan Morgan (E)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Marilly Palettas (M)

Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH, USA.

Julie A Stephens (JA)

Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH, USA.

Joseph Liu (J)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Michael Berger (M)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Pharmacy Department, Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.

Craig Vargo (C)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Pharmacy Department, Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.

Anne Noonan (A)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Raquel Reinbolt (R)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Mathew Cherian (M)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Jeffrey VanDeusen (J)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Sagar Sardesai (S)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Robert Wesolowski (R)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Daniel G Stover (DG)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Maryam Lustberg (M)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Bhuvaneswari Ramaswamy (B)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA.

Nicole Williams (N)

Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA. Nicole.Williams@osumc.edu.
Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA. Nicole.Williams@osumc.edu.
Division of Medical Oncology, The Ohio State University Wexner Medical Center, 1202A Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. Nicole.Williams@osumc.edu.
ORCID: 0000-0002-0339-1612

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Efficacy of different dosing schedules of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Efficacy of different dosing schedules of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions toxiques › Noxas › Antimétabolites › Antimétabolites antinéoplasiques › Efficacy of different dosing schedules of...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Efficacy of different dosing schedules of...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Désoxycytidine › Capécitabine › Efficacy of different dosing schedules of...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Calendrier d'administration des médicaments › Efficacy of different dosing schedules of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Efficacy of different dosing schedules of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Estimation de Kaplan-Meier › Efficacy of different dosing schedules of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Efficacy of different dosing schedules of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Efficacy of different dosing schedules of...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Échec thérapeutique › Efficacy of different dosing schedules of...